3 Monster Dividend Stocks to Hold for the Next 10 Years
View original at nasdaq.com3 Monster Dividend Stocks to Hold for the Next 10 Years Key Points AbbVie is a Dividend King that has demonstrated its ability to adapt effectively to daunting challenges…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
AbbVie is a member of the Dividend Kings with a 53-year streak of consecutive dividend increases, including time as part of Abbott Labs, and a forward dividend yield topping 3.2%
60% confidenceEnterprise Products Partners generated resilient cash flow throughout major energy sector disruptions including the 2007-2009 financial crisis, the 2015-2017 oil price collapse, and the 2020-2022 COVID-19 pandemic
60% confidenceNextEra targets compound annual growth in adjusted earnings per share of at least 8% through 2035
60% confidenceNextEra Energy is also the world leader in renewable energy and battery storage
60% confidenceNextEra expects the dividend to rise by roughly 10% in 2026, followed by an average annual growth rate of approximately 6% through 2028
60% confidenceNextEra Energy ranks as the largest utility company by market cap
60% confidenceIf you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes.
60% confidenceData centers hosting AI applications require massive amounts of electric power; natural gas is a great fit for fueling power plants serving these data centers, which should translate to higher volumes through Enterprise's pipelines
60% confidenceAbbVie's pipeline includes around 90 programs, of which roughly 60 are in mid- or late-stage clinical trials
60% confidenceEnterprise Products Partners pays a distribution yield of 5.5% and has increased its distribution for 27 consecutive years
60% confidenceVirginia is the home to the world's largest data center market
60% confidenceAbbVie's growth barely skipped a beat after Humira lost patent exclusivity, thanks to investments in R&D and smart acquisitions that added new growth drivers
60% confidenceStock Advisor's total average return is 986%, a market-crushing outperformance compared to 208% for the S&P 500
60% confidence
Data points we hold from this source
| AbbVie Inc. · mid late stage clinical trials | 60 programs |
| AbbVie Inc. · consecutive dividend increases | 53 years |
| AbbVie Inc. · pipeline total programs | 90 programs |